Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study

Simple item page
dc.contributor.authorInal A.
dc.contributor.authorKos F.T.
dc.contributor.authorAlgin E.
dc.contributor.authorYildiz R.
dc.contributor.authorDikiltas M.
dc.contributor.authorUnek I.T.
dc.contributor.authorColak D.
dc.contributor.authorElkiran E.T.
dc.contributor.authorHelvaci K.
dc.contributor.authorGeredeli C.
dc.contributor.authorDane F.
dc.contributor.authorBalakan O.
dc.contributor.authorKaplan M.A.
dc.contributor.authorDurnali A.G.
dc.contributor.authorHarputoglu H.
dc.contributor.authorGoksel G.
dc.contributor.authorOzdemir N.
dc.contributor.authorBuyukberber S.
dc.contributor.authorGumus M.
dc.contributor.authorKucukoner M.
dc.contributor.authorOzkan M.
dc.contributor.authorUncu D.
dc.contributor.authorBenekli M.
dc.contributor.authorIsikdogan A.
dc.date.accessioned2024-07-22T08:19:43Z
dc.date.available2024-07-22T08:19:43Z
dc.date.issued2012
dc.description.abstractThe majority of patients with pancreatic cancer is of advanced disease. Several randomized Phase II and III trials suggest that the combination of gemcitabine and cisplatin (GemCis) response rates were higher than Gemcitabine (Gem) alone, however the trials were not enough powered to indicate a statistically significant prolongation of survival in patients with advanced pancreatic adenocarcinoma. The aim of this retrospective multicenter study is to evaluated the efficiency of Gem alone versus GemCis in patients with locally advanced and/or metastatic pancreatic adenocarcinoma. A total of 406 patients, from fourteen centers were evaluated retrospectively. All patients received Gem or GemCis as first-line treatment between September 2005 to March 2011. Primary end of this study were to evaluate the toxicity, clinical response rate, progression-free survival (PFS) and overall survival (OS) between the arms. There were 156 patients (M: 98, F: 58) in Gem arm and 250 patients (M: 175, F: 75) in the combination arm. Gemcitabin arm patients older than the combination arm (median 63 vs 57.5, p=0.001). In patients with the combination arm had a higher dose reduction (25.2% vs 11.3%, p=0.001) and dose delay (34% vs 16.8%, p=0.001). Among patients with the combination and Gemcitabin arm gender, diabetes mellitus, performance status, cholestasis, grade, stage did not have a statistically difference (p>0.05). Clinical response rate to the combination arm was higher than the Gem arm (69.0% vs 49.7%, p=0.001). PFS was more favorable in the GemCis arm than Gem alone, but the difference did not attain statistical significance (8.9 vs 6.0, p=0.08). OS was not significantly superior in the GemCis arm (12.0 vs 10.2, p>0.05). Grade III-IV hematologic and nonhematologic toxicity were higher in the combination arm. PFS was more favorable in the GemCis arm than Gem alone, but the difference did not attain statistical significance. OS was not significantly superior in the GemCis arm.
dc.identifier.DOI-ID10.4149/neo_2012_038
dc.identifier.issn00282685
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17808
dc.language.isoEnglish
dc.publisherSAP - Slovak Academic Press, spol. s.r.o.
dc.rightsAll Open Access; Bronze Open Access
dc.subjectAdenocarcinoma
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectCisplatin
dc.subjectDeoxycytidine
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectLymphatic Metastasis
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeoplasm Staging
dc.subjectPancreatic Neoplasms
dc.subjectRetrospective Studies
dc.subjectSurvival Rate
dc.subjectTreatment Outcome
dc.subjectcisplatin
dc.subjectgemcitabine
dc.subjectantineoplastic agent
dc.subjectcisplatin
dc.subjectdeoxycytidine
dc.subjectdrug derivative
dc.subjectgemcitabine
dc.subjectadult
dc.subjectanemia
dc.subjectarticle
dc.subjectcancer chemotherapy
dc.subjectcomputer assisted tomography
dc.subjectdiarrhea
dc.subjectdrug efficacy
dc.subjectdrug response
dc.subjectdrug safety
dc.subjectfebrile neutropenia
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetastasis
dc.subjectmiddle aged
dc.subjectmultiple cycle treatment
dc.subjectnausea
dc.subjectnephrotoxicity
dc.subjectneutropenia
dc.subjectoverall survival
dc.subjectpancreas carcinoma
dc.subjectprogression free survival
dc.subjectretrospective study
dc.subjectthrombocytopenia
dc.subjecttreatment response
dc.subjectvomiting
dc.subjectadenocarcinoma
dc.subjectcancer staging
dc.subjectclinical trial
dc.subjectfollow up
dc.subjectlymph node metastasis
dc.subjectmetastasis
dc.subjectmortality
dc.subjectmulticenter study
dc.subjectpancreas tumor
dc.subjectpathology
dc.subjectsurvival rate
dc.subjecttreatment outcome
dc.titleGemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu